Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients

Noam Y. Harel, Merit E. Cudkowicz, Robert H. Brown, Stephen M. Strittmatter

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Improved biomarkers would facilitate the diagnosis and treatment of amyotrophic lateral sclerosis (ALS). Muscle content of the neuritic outgrowth inhibitor Nogo-A is increased in patients with ALS and other denervating conditions. Seeking a less invasive diagnostic method, we sought to determine whether or not Nogo increases in the serum of ALS patients. We developed a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) protocol to screen serum samples from 172 ALS patients and 172 healthy controls for Nogo-A immunoreactivity. Unexpectedly, there was a trend toward decreased levels of serum Nogo-A in ALS. Mean serum Nogo-A level in ALS patients was 0.71nM (95% confidence interval (CI) 0.421.00), as opposed to 1.15nM (95% CI 0.721.59) in healthy controls. A significantly larger percentage of healthy control sera (11.0% vs 4.7%) displayed markedly elevated levels of Nogo-A. Additional study is required to determine the factors that lead to elevated Nogo-A levels in a subset of both ALS patients and healthy controls.

Original languageEnglish
Pages (from-to)414-417
Number of pages4
Issue number6
StatePublished - Sep 2009
Externally publishedYes


  • ALS
  • Biomarker
  • Nogo-A


Dive into the research topics of 'Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients'. Together they form a unique fingerprint.

Cite this